Carcinoid Tumors

15 registered clinical trials studyying Carcinoid Tumors.

Status	Trial	Sponsor	Phase
Terminated	Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Live NCT02859064	SCRI Development Innovations, LLC	Phase 2
Completed	A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcin NCT02795858	Dana-Farber Cancer Institute	Phase 2
Completed	Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors NCT02575300	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors NCT02441062	Sue O'Dorisio	Phase 2
Terminated	68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs NCT02359500	Lale Kostakoglu	Phase 1
Terminated	GA-68 DOTA-TOC of Somatostatin Positive Malignancies NCT02177773	University of California, San Francisco	Phase 1 / Phase 2
Unknown	A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metas NCT01731925	GERCOR - Multidisciplinary Oncology Cooperative Group	Phase 2
Completed	Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors NCT01619865	Sue O'Dorisio	Phase 1 / Phase 2
Completed	Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) NCT01253161	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Terminated	A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors NCT00947167	Pamela L. Kunz	Phase 2
Terminated	Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion NCT00227136	University of Western Ontario, Canada	Phase 3
Completed	Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma NCT00580320	Virginia Commonwealth University	Phase 1
Completed	Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors NCT00088595	Novartis Pharmaceuticals	Phase 2
No Longer Available	68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors NCT01980732	Andrei Iagaru	—
Unknown	123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors NCT01373736	Vancouver Coastal Health	Phase 3